GSK and AstraZeneca reveal Covid-19 breakthrough ahead of Q1 results

Britain’s largest drug makers revealed major breakthroughs in the fight against Covid-19 earlier this month, supporting their share prices ahead of their Q1 results next week.

GlaxoSmithKline (GSK) and AstraZeneca recently revealed major breakthroughs in the fight against the Covid-19 crisis, helping to support their respective share prices ahead of their first quarter (Q1) results next week.

Earlier this month, AstraZeneca said it was fast-tracking a clinical trial for its blood cancer drug Calquence, with the drug maker hoping that it will improve severely ill patients chances of surviving the coronavirus.

Meanwhile, its rival GSK announced a partnership with French drug maker Sanofi, with the pair working together to manufacture a Covid-19 vaccine.

If successful, the pair’s capacity will allow them to manufacture hundreds of millions of doses that are likely to be required worldwide.

Sanofi will contribute its S-protein Covid-19 antigen, which is based on recombinant DNA technology, while GSK will contribute its proven pandemic adjuvant technology to the collaboration.

The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

‘By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from Covid-19,’ GSK CEO Emma Walmsley said.

Clinical trials for the vaccine are expected to begin later this year.

GSK and AstraZeneca shares rally ahead of Q1 results

Since hitting a low of £13.74 a share on 23 March, GSK shares have shown signs of recovery, with the stock climbing 21% over the last five weeks to trade at £16.80 a share as of 12:30 (GMT) on Thursday.

Meanwhile, AstraZeneca has climbed more than 18% over the same period, with the stock up 5% on a year-to-date basis, outperforming the broader market with the FTSE 100 24% down since the start of the year.

Both drug makers will unveil their Q1 results on Wednesday 29 April, with their performance in 2020 heavily dependent on the severity of the economic fallout from the Covid-19 pandemic.

AstraZeneca is looking to increase its total revenue by a ‘high single-digit to a low double-digit percentage’ and its core earnings per share (EPS) is forecast to increase by a ‘mid- to high-teens percentage’, according to its previous guidance.

GSK is expecting adjusted EPS to decline by -1% to -4% CER and is targeting a dividend pay-out of 80p per share in 2020.

Investors will be interested to see the impact of the coronavirus on both drug markers performance over their first three months of trading, though most companies guidance this year is heavily weighted towards the latter half of 2020.

How to trade stocks with IG

Looking to trade GSK and other stocks? Open a live or demo account with IG and buy (long) or sell (short) the asset using derivatives like CFDs in a few easy steps:

  • Create an IG trading account or log in to your existing account

  • Enter ‘Metro Bank’ in the search bar and select it

  • Choose your position size

  • Click on ‘buy’ or ‘sell’ in the deal ticket

  • Confirm the trade

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

React to global volatility

Market volatility continues as coronavirus concerns amplify. Trade with IG and take advantage of:

  • Tight spreads – from just 1 point on major indices, and 2.8 on US crude
  • Guaranteed stops – they’re free to use, and only incur a fee when triggered
  • Round-the-clock assistance – our highly skilled team are available when you need support

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.


Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.